← Back to guidelines
Pathology57 papers

Clear cell urothelial carcinoma

Last edited: 4/15/2026

Overview

Clear cell urothelial carcinoma is a rare variant of urothelial carcinoma characterized by clear cells within the tumor architecture, presenting unique diagnostic and management challenges within the broader spectrum of bladder cancers 2.

Diagnosis

  • Histopathological Examination: Essential for diagnosis, involving biopsy or transurethral resection specimens 2.
  • Digital Pathology: Utilization of digitized slides for enhanced analysis and grading 2.
  • Grading: Follows the World Health Organization (WHO) grading system (papillary, low-grade/high-grade) 2.
  • Interobserver Variability: High variability noted among pathologists; automated grading systems show moderate agreement with consensus readings (κ = 0.48 ± 0.14 SEM) 2.
  • Management

  • Surgical Resection: Primary treatment often involves transurethral resection or cystectomy, depending on tumor stage and grade 2.
  • Adjuvant Therapy: Not specifically detailed in provided abstracts; typically guided by standard urothelial carcinoma guidelines 2.
  • Follow-Up: Regular surveillance cystoscopy and imaging to monitor recurrence 2.
  • Special Populations

  • No Specific Data: Abstracts do not provide specific guidance or data regarding management in pregnancy, pediatrics, elderly patients, or those with comorbidities 12.
  • Key Recommendations

  • Utilize histopathological examination with digital pathology for accurate diagnosis and grading of clear cell urothelial carcinoma (Evidence: Moderate) 2.
  • Consider automated grading systems to mitigate interobserver variability in tumor grading (Evidence: Moderate) 2.
  • Implement standard surgical resection techniques followed by tailored adjuvant therapy based on conventional urothelial carcinoma guidelines (Evidence: Expert opinion) 2.
  • References

    1 Chyu J, Peters CE, Nicholson TM, Dai JC, Taylor J, Garg T et al.. Women in Leadership in Urology: The Case for Increasing Diversity and Equity. Urology 2021. link 2 Jansen I, Lucas M, Bosschieter J, de Boer OJ, Meijer SL, van Leeuwen TG et al.. Automated Detection and Grading of Non-Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. The American journal of pathology 2020. link

    Original source

    1. [1]
      Women in Leadership in Urology: The Case for Increasing Diversity and Equity.Chyu J, Peters CE, Nicholson TM, Dai JC, Taylor J, Garg T et al. Urology (2021)
    2. [2]
      Automated Detection and Grading of Non-Muscle-Invasive Urothelial Cell Carcinoma of the Bladder.Jansen I, Lucas M, Bosschieter J, de Boer OJ, Meijer SL, van Leeuwen TG et al. The American journal of pathology (2020)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG